Spotlight On... Just wait, Momenta CEO says. Novartis' generic can bring down Copaxone; Novo, AZ await results of key clinical trials; Health Canada green-lights Bristol-Myers immunotherapy Opdivo; and more...

Thanks to some aggressive brand defense tactics, Teva's ($TEVA) multiple sclerosis blockbuster Copaxone has been hanging onto its slice of the pie despite generic competition from Novartis' ($NVS) Sandoz and Momenta ($MNTA). But it's all a matter of time until Sandoz manages to cut down Teva's market share, Momenta CEO Craig Wheeler recently promised investors. Sandoz has "the capabilities necessary" and is "focused on countering" the Israeli drugmaker's strategy, he said. More from FiercePharmaMarketing

@FiercePharma: Bayer incoming CEO highlights OTC challenges in China in three-way integration. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Pressed by reporters, Valeant 'fesses up to SEC investigation. Report | Follow @CarlyHFierce

> Novo Nordisk ($NVO) and AstraZeneca ($AZN) each are awaiting results of key clinical trials, with Novo hoping for solid heart results for its diabetes drug Victoza and AZ looking toward results in stroke patients for its blood thinner Brilinta. Report

> Health Canada handed a new approval to Bristol-Myers Squibb's ($BMY) cancer immunotherapy Opdivo, in patients with advanced non-small cell lung cancer. Release

> Another set of women have sued GlaxoSmithKline ($GSK) over birth defects they say are linked to the morning sickness drug Zofran. Report

> Novo Nordisk rolled out the results of a study that suggests its new combination diabetes treatment Xultophy is cost effective compared with other step-up treatments for patients on basal insulin alone. Release

> Dublin's Perrigo ($PRGO) says it expects a $100 million boost to annual sales from a new factory in Israel. Report

> U.S. drug distributor McKesson ($MCK) is beefing up in Canada with a $2.23 billion agreement to buy drugstore chain Rexall Health. Report

Medical Device News

@FierceMedDev: Scientists create digital 'magic wand' to improve at-home device cybersecurity. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI: Voice box maker Atos Medical goes on the chopping block for €1 billion: WSJ. Story | Follow @EmilyWFierce

> Olympus to fork over $646M to DOJ over bribery scandal in largest-ever medical device settlement. Article

> Smith & Nephew touts its new 3-D printed hip implant. More

> Zimmer buys Ortho Transmission to better serve amputees using novel surgical approach. News

Biotech News

@FierceBiotech: Merck launches late-stage trials for Humira biosimilar. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree. Article | Follow @JohnCFierce

> Rare-disease specialist Alexion hails progress on Sanfilippo B drug. Report

> J&J opens the doors to its new biotech hub in Houston. Article

Biotech Research News

> Stanford researchers show glucose-binging immune cells central to coronary artery disease. More

> Clearing inflammatory cells improves memory in a mouse model for Alzheimer's. Story

> Texas Tech team experiments with CRISPR/Cas9 upgrade. Item

> Single monoclonal antibody shows promise in pre-clinical Ebola virus disease. Report

> Molecular 'brake' curbs inflammation, could combat aging. Article

Pharma Marketing News

> Amgen hits Sandoz with patent infringement suit over Enbrel biosim. Item

> Dancing bladders and football-helmeted toenails have FDA questioning cartoons in DTC ads. Report

> Free speech crops up in another off-label marketing legal victory for industry. Article

> Don't give up on biosim Copaxone, despite Teva's aggressive brand defense: Momenta CEO. More

> Talk show host Dr. Phil has a new subject: AstraZeneca's Bydureon. Story

Vaccines News

> U.K. rejects petition demanding meningitis B vaccine for all children. More

> Novavax explores Zika vaccine R&D effort as virus continues to spread. Report

> Seqirus to build new U.K. manufacturing outpost. Item

> U.S. Army, GSK's P. vivax malaria vaccine fails to protect in early trial. Story

> New South Korean study could help direct MERS vaccine development. Article

And Finally... Johnson & Johnson ($JNJ) has paired up with LifeScan on blood glucose monitoring. Report

Suggested Articles

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.

GSK is grouping some non-core consumer products into three portfolios for sell-offs so it can win EU antitrust clearance for its Pfizer deal.